These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-005972-34 Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten not-yet-due
Not reported 2006-002464-26 EFFEKTEN AF VELCADE PÅ KNOGLEVÆVET VED MYELOMATOSE (KNOGLEMARVSKRÆFT). 2009-07-07 due-trials
Completed, but no date 2006-005756-32 Pharmacological modulation of the intrarenal pressure during endourological procedures in the upper urinary tract bad-data
Not reported 2007-003777-13 Knoglebinding af bisfosfonat (Zometa) hos patienter med myelomatose eller brystkræft med knoglemetastaser 2012-01-04 due-trials
Ongoing 2007-003890-20 Postoperativ smertebehandling efter total hoftealloplastik not-yet-due
Completed, but no date Terminated 2007-004791-39 Et prospektivt randomiseret fase II studie til evaluering af Gabapentin bad-data
Ongoing 2007-007137-38 En åbent randomiseret fase II undersøgelse af effekten af darbepoietin alfa (Aranesp®) til behandling af anæmi hos patienter med hormonrefraktær prostatacancer, der behandles med Taxotere not-yet-due
Not reported 2008-000878-20 Bevacizumab og Carboplatin til patienter med platinresistent epithelial ovariecancer 2015-08-04 due-trials
Not reported 2008-002367-14 Kombineret biologisk behandling og kemoterapi til patienter med inoperabelt cholangiocarcinom 2016-03-31 due-trials
Not reported 2008-003962-24 visceral pain originating from the upper urinary tract - a randomised controlled trial on the effect of morphine and oxycodone in patients undergoing percutaneus nephrolithotomy (PCNL) 2012-06-26 due-trials
Not reported Terminated 2008-004923-48 En fase II undersøgelse af Irinotecan og Panitumumab som 3. linje behandling til patienter med metastaserende colorectal cancer uden KRAS mutationer. 2012-11-19 due-trials
Not reported 2008-007665-22 En fase II undersøgelse af Temsirolimus og Irinotecan til behandlingsresistente patienter med metastaserende colorectal cancer og KRAS mutationer 2011-02-03 due-trials
Listed as ongoing, but also has a completion date 2008-007799-13 Panitumumab and Pegylated Liposomal Doxorubicin to Platinum-Resistant Epithelial Ovarian Cancer with KRAS Wild-type 2012-10-31 bad-data
Not reported Terminated 2009-010539-41 Norspan versus Oxycontin som postoperativ smertebehandling til ekstracapsulære femurfraktur. 2013-05-01 due-trials
Not reported 2009-015068-32 ”Et fase II-forsøg med standardkemoterapi og panitumumab til pati-enter med metastaserende NSCL udvalgt på basis af mutationsstatus" 2013-11-15 due-trials
Not reported Terminated 2010-018700-90 En fase II undersøgelse af pemetrexed og gemcitabin til behandlingsresistente patienter med KRAS muteret metastaserende colorectal cancer 2011-08-16 due-trials
Not reported 2010-020385-13 Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations 2016-03-31 due-trials
Completed, but no date Terminated 2010-021618-42 En fase II undersøgelse af oral vinorelbin i kombination med trastuzumab til 1. og 2. linie behandling af kvinder med metastaserende HER2 positiv brystkræft bad-data
Completed, but no date 2010-024050-10 Vertebroplasty versus periost infiltration with lidocain as pain treatment in osteoporotic fractures in the thoracic and lumbar spine bad-data
Exempt 2011-002099-18 Veliparib (ABT888) Monotherapy for Patients with BRCA germline mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer 2016-01-29 not-yet-due
Reported results 2011-002751-34 An Open-Label Phase II Study of the Safety and Efficacy of Doxorubicin and Cyclophosphamide in Combination with Bortezomib, Lenalidomide, and Dexamethasone for Treatment of Patients with Newly Diagn... 2017-09-28 due-trials
Completed, but no date 2011-004182-33 Phase II Study of gemcitabin and capecitabine in Chemotherapy Refractory Metastatic Colorectal Cancer bad-data
Completed, report not yet due 2011-006152-36 Postoperative treatment with parathyroidea hormone Forteo® in patients undergoing posterolateral spinal fusion surgery. A prospektive and a randomized double-blinded, placebo-controlled study 2018-06-13 not-yet-due
Not reported Terminated 2012-001224-35 Cabazitaxel in platinum refractory ovarian cancer. A phase II trial 2014-07-01 due-trials
Exempt 2012-001661-32 Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status 2015-02-01 not-yet-due
Not reported Terminated 2012-001924-37 Relaxation of the ureter during ureterorenoscopy 2014-06-13 due-trials
Not reported 2012-004354-28 Maintenance treatment in childhood constipation. 2015-09-24 due-trials
Ongoing 2013-002363-26 Neoadjuvant chemotherapy versus standard treatment in patients with locally advanced colon cancer not-yet-due
Completed, report not yet due Terminated 2013-004475-13 Pharmacological relaxation of the ureter when using access sheaths during ureterorenoscopy 2018-09-28 not-yet-due
Ongoing 2013-004858-18 Tocotrienol as a nutritional supplement in patients with advanced ovarian cancer not-yet-due
Not reported 2014-005189-31 “Monoclonal antibodies for treatment of multiple myeloma. Present status and aspects of effector mechanisms with emphasis on the CD38 antibody daratumumab ”. 2015-10-01 due-trials
Ongoing 2015-002296-18 Cabazitaxel in patients with Recurrent Ovarian Cancer after failure of standard therapy- A phase II trial not-yet-due
Ongoing 2015-002326-39 The influence of fat intake, estrogen, age, and gender on postprandial lipds and glucose not-yet-due
Ongoing 2015-002742-32 Tocotrienol as a nutritional supplement in patients with advanced pulmonal cancer not-yet-due
Ongoing 2015-004850-17 A randomized investigation of side effects to FOLFOXIRI in combination with tocotrienol or placebo as first line treatment of metastatic colorectal cancer. not-yet-due
Ongoing 2016-000080-16 Tocotrienol in combination with neoadjuvant chemotherapy for women with breast cancer not-yet-due
Ongoing 2017-000456-26 Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumorspheres from patients with metastatic colorectal cancer not-yet-due
Ongoing 2018-003112-53 Predictive value of in-vitro testing anti-cancer therapy sensitivity on tumoroids from patients with metastatic pancreatic cancer not-yet-due
Ongoing 2019-000618-13 Bevacizumab and tocotrienol in recurrent ovarian cancer. A marker based phase II trial not-yet-due